focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTILS.L Regulatory News (TILS)

  • There is currently no data for TILS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

New Study published

26 Jun 2008 10:00

RNS Number : 5505X
ReGen Therapeutics PLC
26 June 2008
 



Embargoed for 10am 26 June 2008

ReGen Therapeutics Plc

Study showing that ReGen's ColostrininTM protects hippocampal cells against beta-amyloid and oxidative stress is to be presented at the FENS Forum 2008

ReGen Therapeutics Plc ('ReGen' or 'the Company') announces the publication of a new study showing that ReGen's ColostrininTM protects hippocampal cells against beta-amyloid and oxidative stress. The research, which has been performed by ReGen's collaborators at the Open University, Milton Keynes, United Kingdom is to be presented as a poster at the FENS Forum 2008*, Geneva on 16 July 2008.It has previously been shown that Colostrinin™ can prevent beta-amyloid induced impairment of learning in newly hatched chicks [1] and can protect standardised laboratory neurological cells against beta-amyloid induced toxicity and oxidative stress induced damage [2]. However, the research presented at the FENS Forum is the first study to show these effects on isolated hippocampal cells. 

Commenting on the study, Professor Mike Stewart the senior investigator and scientific advisor to ReGen said 

"These findings are very significant as the hippocampus is one of the key brain areas known to be affected in neurodegenerative diseases such as Alzheimer's disease. It is of particular importance to note that Colostrinin™ can directly protect these neurons that have such an important role in cognition and memory".

Percy Lomax, Chairman and Chief Executive of ReGen said

"This research gives us further confidence in promoting Colostrinin™/CogniSure™ as a nutraceutical for healthy brain ageing. Longer term it adds to our belief that our peptide programme may be able to produce a pharmaceutical product with utility in Alzheimer's disease and other similar neurological disease conditions".

A copy of the full abstract is available at:

http://fens2008.neurosciences.asso.fr/pages/posters_sessions.html 

(Poster session 7 - Wednesday, July 16, 09:30-13:00, Section P217 - C: Alzheimer's 4). Froud K., Saffrey M. J., Stewart M. G., Banks D. & Wardhaugh T. 

* The FENS Forum is the premier European Neuroscience meeting of 2008 

1. Boldogh, I, Kruzel, M. L Journal of Alzheimer's Disease 13 (2008) 303-321  2. Banks D, Stewart M. G. Soc Neurosci Abstr proceedings (2006) 674.5.

 

For further information:

Percy Lomax

ReGen Therapeutics Plc

Tel No 020 7153 4920

Roland Cornish/Felicity Geidt

Beaumont Cornish

Tel No 020 7628 3396

David Scott/Nick Bealer

Alexander David

Tel No 020 7448 9800

Adrian Duffield/Jon Davies

College Hill Associates

Tel No 020 7457 2020

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCKGGZVKKKGRZM
Date   Source Headline
21st Apr 20204:40 pmRNSSecond Price Monitoring Extn
21st Apr 20204:36 pmRNSPrice Monitoring Extension
21st Apr 20207:00 amRNSNotice of GM
16th Apr 20209:05 amRNSSecond Price Monitoring Extn
16th Apr 20209:00 amRNSPrice Monitoring Extension
15th Apr 20204:31 pmRNSFurther Re: Block Listing Application
15th Apr 202011:05 amRNSSecond Price Monitoring Extn
15th Apr 202011:00 amRNSPrice Monitoring Extension
15th Apr 20207:00 amRNSBlock Listing Application
15th Apr 20207:00 amRNSIssue of Equity
14th Apr 20204:41 pmRNSSecond Price Monitoring Extn
14th Apr 20204:37 pmRNSPrice Monitoring Extension
14th Apr 202011:06 amRNSSecond Price Monitoring Extn
14th Apr 202011:01 amRNSPrice Monitoring Extension
9th Apr 20207:00 amRNSTiziana Develops Treatment For COVID-19 Patients
16th Mar 20205:21 pmRNSClosing of Offer
12th Mar 20207:00 amRNSTiziana U.S. Follow-On Offering of $10 million
11th Mar 20207:00 amRNSTZLS-501 / COVID-19
20th Feb 202010:30 amRNSResult of GM
17th Feb 20207:00 amRNSProposed U.S. Public Offering of ADSs
4th Feb 202012:00 pmRNSDirector/PDMR Shareholding
3rd Feb 20207:00 amRNSNotice of GM
23rd Jan 20207:00 amRNSFiling of SEC Form F-3
21st Jan 20202:45 pmRNSDirector Appointment
14th Jan 202011:00 amRNSDirector/PDMR Shareholding
13th Jan 20207:00 amRNSProposed Cancellation from AIM
9th Jan 20207:00 amRNSFurther re: Foralumab Phase 1 Trial
2nd Jan 20203:00 pmRNSDirector/PDMR Shareholding
4th Dec 20197:00 amRNSForalumab Phase 1 Trial
20th Nov 20197:00 amRNSIssue of Equity and Directorate Change
1st Nov 20197:00 amRNSIssue of CLN
30th Oct 201910:31 amRNSChange to ADS ratio
30th Sep 20197:00 amRNSHalf-year Report
16th Sep 20197:00 amRNSFurther re: Update on IND Application
10th Sep 20197:00 amRNSPhase 1 Clinical Data
4th Sep 20197:00 amRNSPhase 2a Clinical Data
21st Aug 20194:40 pmRNSSecond Price Monitoring Extn
21st Aug 20194:35 pmRNSPrice Monitoring Extension
6th Aug 20197:00 amRNSProposed U.S. Public Offering
22nd Jul 20197:00 amRNSPhase 2a Clinical Data
1st Jul 20197:00 amRNSTeplizumab Article
28th Jun 20194:40 pmRNSSecond Price Monitoring Extn
28th Jun 20194:35 pmRNSPrice Monitoring Extension
28th Jun 201910:54 amRNSChange of Adviser
25th Jun 20197:00 amRNSDirector/PDMR Shareholding
24th Jun 20197:00 amRNSArticle on Clinical Activity of OKT3
11th Jun 20197:00 amRNSDirector/PDMR Shareholding
7th Jun 20199:44 amRNSDirector/PDMR Shareholding
3rd Jun 20197:00 amRNSPDMR Dealings
31st May 201911:05 amRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.